Pfizer has announced it will acquire exclusive global rights to the over-the-counter (OTC) version of AstraZeneca‘s Nexium, a heartburn treatment, for $250m.
AstraZeneca will retain the rights to manufacture and market the prescription version of the drug and will also be eligible to receive milestone and royalty payments from Pfizer, based upon the launch and sales of the OTC version.
Pfizer has confirmed it expects to market the OTV version of Nexium in 2014, coinciding with the prescription version of the drug losing its patent protection. The company also confirmed that a marketing application for the pill was filed with European regulators in June 2012, and a similar application will be filed with the US Food and Drug Administration in the first half of 2013.
Despite being AstraZeneca’s second-largest seller in Q2 2012, Nexium has been hit by generic competition that has seen its revenue fall. Revenue from the acid reflux medication fell 13% to $949m during the quarter.
As per the terms of the agreement, AstraZeneca will supply Pfizer with OTC Nexium upon regulatory approval, and both companies will consider similar partnerships for other AstraZeneca prescription drugs for which OTC versions could be made available.
AstraZeneca Global Commercial Organisation executive vice president Tony Zook said; "AstraZeneca has long been a leader in the gastrointestinal sector, and we believe that an OTC version of Nexium will complement this globally successful prescription medicine and help bring relief to more patients around the world."
How well do you really know you competitors?
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
"This agreement will help AstraZeneca realise the substantial, long-term value of this brand and potentially other brands in our portfolio," added Zook.
Image: Pfizer corporate headquarters, located in New York, US. Photo: Courtesy of Pfizer.